Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 4/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL9468295 | 0.99 | PNP (0.46) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Guanine SCHEMBL15718981 | 0.96 | PNP (0.43) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Guanine SCHEMBL9468227 | 0.95 | PNP (0.43) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL4579097 | 0.93 | PI4KA (0.46) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Guanine SCHEMBL23880590 | 0.92 | PNP (0.55) | PNPGDAATAD2 | |
| Guanine SCHEMBL2526275 | 0.92 | PNP (0.55) | PNPGDAATAD2 | |
| Guanine SCHEMBL20518478 | 0.92 | PNP (0.55) | PNPGDAATAD2 | |
| Guanine SCHEMBL17597606 | 0.92 | PNP (0.55) | PNPGDAATAD2 | |
| Guanine SCHEMBL6130674 | 0.91 | PNP (0.58) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Guanine SCHEMBL4348108 | 0.91 | PNP (0.58) | PNPPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4368990-A2 | CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDE | Gentium S.r.l. (IT) | 2024-05-15 | — | — | EP | disclosed |
| EP-3748358-B1 | CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDE | GENTIUM S R L (IT) | 2023-12-27 | — | — | EP | disclosed |
| US-20230194502-A1 | CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDE | GENTIUM S.R.L. (IT) | 2023-06-22 | — | — | US | disclosed |
| CN-107109458-B | Cell-based defibrotide potency assay | 真蒂奥姆责任有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3748358-A1 | CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDE | Gentium S.r.l. (IT) | 2020-12-09 | — | — | EP | disclosed |
| EP-3120153-B1 | CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDE | GENTIUM S R L (IT) | 2020-08-19 | — | — | EP | disclosed |
| US-20200197351-A1 | TRIVALENT AND DIVALENT CATIONS AS ADMINISTRABLE AGENTS FOR INCREASED PROCESSIVITY AND IMPROVED FIDELITY OF REVERSE TRANSCRIPTASE IN TELOMERASE AND IN NUCLEIC ACID POLYMERASES | FILLER AARON GERSHON (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200057051-A1 | CELLULAR-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | GENTIUM S.R.L. (IT) | 2020-02-20 | — | — | US | disclosed |
| US-10393731-B2 | Cellular-based method for determining the biological activity of defibrotide | GENTIUM S.R.L. (IT) | 2019-08-27 | — | — | US | disclosed |
| US-10364272-B2 | Conformationally-preorganized, miniPEG-containing gamma-peptide nucleic acids | CARNEGIE MELLON UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20050216083-A1 | Method for inserting a fusion cage having a height substantially the same as the height between adjacent vertebral endplates | WARSAW ORTHOPEDIC, INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1554995-A2 | Self-broaching, rotatable, push-in interbody spinal implant | Michelson, Gary Karlin (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1131020-B1 | SELF-BROACHING, ROTATABLE, PUSH-IN INTERBODY FUSION IMPLANT | MICHELSON GARY K (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20030149483-A1 | Self-broaching, rotatable, push-in interbody spinal fusion implant and method for deployment thereof | WARSAW ORTHOPEDIC, INC. | 2003-08-07 | — | — | US | disclosed |
| EP-1131020-A4 | SELF-BROACHING, ROTATABLE, PUSH-IN INTERBODY FUSION IMPLANT AND METHOD FOR DEPLOYMENT THEREOF | MICHELSON GARY K (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6537320-B1 | Self-broaching, rotatable, push-in interbody spinal fusion implant and method for deployment thereof | WARSAW ORTHOPEDIC, INC. | 2003-03-25 | — | — | US | disclosed |
| US-20010047207-A1 | Self-broaching, rotatable, push-in interbody spinal fusion implant and method for deployment thereof | WARSAW ORTHOPEDIC, INC | 2001-11-29 | — | — | US | disclosed |
| EP-1131020-A1 | SELF-BROACHING, ROTATABLE, PUSH-IN INTERBODY FUSION IMPLANT AND METHOD FOR DEPLOYMENT THEREOF | MICHELSON, Gary Karlin (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000025707-A9 | SELF-BROACHING, ROTATABLE, PUSH-IN INTERBODY FUSION IMPLANT AND METHOD FOR DEPLOYMENT THEREOF | MICHELSON GARY K (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000025707-A1 | SELF-BROACHING, ROTATABLE, PUSH-IN INTERBODY FUSION IMPLANT AND METHOD FOR DEPLOYMENT THEREOF | MICHELSON GARY K (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364272-B2 | Conformationally-preorganized, miniPEG-containing gamma-peptide nucleic acids | POLL, PCNA, POLG | PNP 421/4885PI4KA 1915/4885PI4K2B 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.